Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 44

3.

Safety of tenofovir use during pregnancy: early growth outcomes in HIV-exposed uninfected infants.

Siberry GK, Williams PL, Mendez H, Seage GR 3rd, Jacobson DL, Hazra R, Rich KC, Griner R, Tassiopoulos K, Kacanek D, Mofenson LM, Miller T, DiMeglio LA, Watts DH; Pediatric HIV/AIDS Cohort Study (PHACS).

AIDS. 2012 Jun 1;26(9):1151-9. doi: 10.1097/QAD.0b013e328352d135.

4.

Prevention of HIV-1 infection with early antiretroviral therapy.

Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, Hakim JG, Kumwenda J, Grinsztejn B, Pilotto JH, Godbole SV, Mehendale S, Chariyalertsak S, Santos BR, Mayer KH, Hoffman IF, Eshleman SH, Piwowar-Manning E, Wang L, Makhema J, Mills LA, de Bruyn G, Sanne I, Eron J, Gallant J, Havlir D, Swindells S, Ribaudo H, Elharrar V, Burns D, Taha TE, Nielsen-Saines K, Celentano D, Essex M, Fleming TR; HPTN 052 Study Team.

N Engl J Med. 2011 Aug 11;365(6):493-505. doi: 10.1056/NEJMoa1105243. Epub 2011 Jul 18.

5.

Triple antiretroviral compared with zidovudine and single-dose nevirapine prophylaxis during pregnancy and breastfeeding for prevention of mother-to-child transmission of HIV-1 (Kesho Bora study): a randomised controlled trial.

Kesho Bora Study Group, de Vincenzi I.

Lancet Infect Dis. 2011 Mar;11(3):171-80. doi: 10.1016/S1473-3099(10)70288-7. Epub 2011 Jan 13. Erratum in: Lancet Infect Dis. 2011 Mar;11(3):159. Read, Jennifer S [corrected to Read, Jennifer].

PMID:
21237718
6.

Concentrations of tenofovir and emtricitabine in breast milk of HIV-1-infected women in Abidjan, Cote d'Ivoire, in the ANRS 12109 TEmAA Study, Step 2.

Benaboud S, Pruvost A, Coffie PA, Ekouévi DK, Urien S, Arrivé E, Blanche S, Théodoro F, Avit D, Dabis F, Tréluyer JM, Hirt D.

Antimicrob Agents Chemother. 2011 Mar;55(3):1315-7. doi: 10.1128/AAC.00514-10. Epub 2010 Dec 20.

7.

Effects of in utero antiretroviral exposure on longitudinal growth of HIV-exposed uninfected infants in Botswana.

Powis KM, Smeaton L, Ogwu A, Lockman S, Dryden-Peterson S, van Widenfelt E, Leidner J, Makhema J, Essex M, Shapiro RL.

J Acquir Immune Defic Syndr. 2011 Feb 1;56(2):131-8. doi: 10.1097/QAI.0b013e3181ffa4f5.

8.

Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.

Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, Vargas L, Goicochea P, Casapía M, Guanira-Carranza JV, Ramirez-Cardich ME, Montoya-Herrera O, Fernández T, Veloso VG, Buchbinder SP, Chariyalertsak S, Schechter M, Bekker LG, Mayer KH, Kallás EG, Amico KR, Mulligan K, Bushman LR, Hance RJ, Ganoza C, Defechereux P, Postle B, Wang F, McConnell JJ, Zheng JH, Lee J, Rooney JF, Jaffe HS, Martinez AI, Burns DN, Glidden DV; iPrEx Study Team.

N Engl J Med. 2010 Dec 30;363(27):2587-99. doi: 10.1056/NEJMoa1011205. Epub 2010 Nov 23.

9.

Prospective study of renal function in HIV-infected pediatric patients receiving tenofovir-containing HAART regimens.

Soler-Palacín P, Melendo S, Noguera-Julian A, Fortuny C, Navarro ML, Mellado MJ, Garcia L, Uriona S, Martín-Nalda A, Figueras C.

AIDS. 2011 Jan 14;25(2):171-6. doi: 10.1097/QAD.0b013e328340fdca.

PMID:
21076275
10.

High prevalence of and progression to low bone mineral density in HIV-infected patients: a longitudinal cohort study.

Bonjoch A, Figueras M, Estany C, Perez-Alvarez N, Rosales J, del Rio L, di Gregorio S, Puig J, Gómez G, Clotet B, Negredo E; Osteoporosis Study Group.

AIDS. 2010 Nov 27;24(18):2827-33. doi: 10.1097/QAD.0b013e328340a28d.

PMID:
21045635
11.

Tenofovir disoproxil fumarate and bone mineral density: a 60-month longitudinal study in a cohort of HIV-infected youths.

Viganò A, Zuccotti GV, Puzzovio M, Pivetti V, Zamproni I, Cerini C, Fabiano V, Giacomet V, Mora S.

Antivir Ther. 2010;15(7):1053-8. doi: 10.3851/IMP1650.

PMID:
21041922
12.

PRO2000 vaginal gel for prevention of HIV-1 infection (Microbicides Development Programme 301): a phase 3, randomised, double-blind, parallel-group trial.

McCormack S, Ramjee G, Kamali A, Rees H, Crook AM, Gafos M, Jentsch U, Pool R, Chisembele M, Kapiga S, Mutemwa R, Vallely A, Palanee T, Sookrajh Y, Lacey CJ, Darbyshire J, Grosskurth H, Profy A, Nunn A, Hayes R, Weber J.

Lancet. 2010 Oct 16;376(9749):1329-37. doi: 10.1016/S0140-6736(10)61086-0. Epub 2010 Sep 17.

13.

Comparison of changes in bone density and turnover with abacavir-lamivudine versus tenofovir-emtricitabine in HIV-infected adults: 48-week results from the ASSERT study.

Stellbrink HJ, Orkin C, Arribas JR, Compston J, Gerstoft J, Van Wijngaerden E, Lazzarin A, Rizzardini G, Sprenger HG, Lambert J, Sture G, Leather D, Hughes S, Zucchi P, Pearce H; ASSERT Study Group.

Clin Infect Dis. 2010 Oct 15;51(8):963-72. doi: 10.1086/656417.

PMID:
20828304
14.

Antiretroviral therapy and preterm delivery-a pooled analysis of data from the United States and Europe.

Townsend C, Schulte J, Thorne C, Dominguez KI, Tookey PA, Cortina-Borja M, Peckham CS, Bohannon B, Newell ML; Pediatric Spectrum of HIV Disease Consortium, the European Collaborative Study and the National Study of HIV in Pregnancy and Childhood.

BJOG. 2010 Oct;117(11):1399-410. doi: 10.1111/j.1471-0528.2010.02689.x. Epub 2010 Aug 17.

15.

Antiretroviral regimens in pregnancy and breast-feeding in Botswana.

Shapiro RL, Hughes MD, Ogwu A, Kitch D, Lockman S, Moffat C, Makhema J, Moyo S, Thior I, McIntosh K, van Widenfelt E, Leidner J, Powis K, Asmelash A, Tumbare E, Zwerski S, Sharma U, Handelsman E, Mburu K, Jayeoba O, Moko E, Souda S, Lubega E, Akhtar M, Wester C, Tuomola R, Snowden W, Martinez-Tristani M, Mazhani L, Essex M.

N Engl J Med. 2010 Jun 17;362(24):2282-94. doi: 10.1056/NEJMoa0907736.

16.

Neonatal, postneonatal, childhood, and under-5 mortality for 187 countries, 1970-2010: a systematic analysis of progress towards Millennium Development Goal 4.

Rajaratnam JK, Marcus JR, Flaxman AD, Wang H, Levin-Rector A, Dwyer L, Costa M, Lopez AD, Murray CJ.

Lancet. 2010 Jun 5;375(9730):1988-2008. doi: 10.1016/S0140-6736(10)60703-9. Epub 2010 May 27. Erratum in: Lancet. 2010 Aug 28;376(9742):686. Lancet. 2010 Jun 19;375(9732):2142.

PMID:
20546887
17.

Impact of antiretroviral therapy on incidence of pregnancy among HIV-infected women in Sub-Saharan Africa: a cohort study.

Myer L, Carter RJ, Katyal M, Toro P, El-Sadr WM, Abrams EJ.

PLoS Med. 2010 Feb 9;7(2):e1000229. doi: 10.1371/journal.pmed.1000229.

18.

Effect of tenofovir disoproxil fumarate on risk of renal abnormality in HIV-1-infected children on antiretroviral therapy: a nested case-control study.

Judd A, Boyd KL, Stöhr W, Dunn D, Butler K, Lyall H, Sharland M, Shingadia D, Riordan A, Gibb DM.

AIDS. 2010 Feb 20;24(4):525-34. doi: 10.1097/QAD.0b013e3283333680.

PMID:
20139752
19.

Elevations in mortality associated with weaning persist into the second year of life among uninfected children born to HIV-infected mothers.

Kuhn L, Sinkala M, Semrau K, Kankasa C, Kasonde P, Mwiya M, Hu CC, Tsai WY, Thea DM, Aldrovandi GM.

Clin Infect Dis. 2010 Feb 1;50(3):437-44. doi: 10.1086/649886.

20.

Early clinical and programmatic outcomes with tenofovir-based antiretroviral therapy in Zambia.

Chi BH, Mwango A, Giganti M, Mulenga LB, Tambatamba-Chapula B, Reid SE, Bolton-Moore C, Chintu N, Mulenga PL, Stringer EM, Sheneberger R, Mwaba P, Stringer JS.

J Acquir Immune Defic Syndr. 2010 May 1;54(1):63-70. doi: 10.1097/QAI.0b013e3181c6c65c.

Supplemental Content

Support Center